Charles Schwab’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $756K | Buy |
577,435
+447,511
| +344% | +$618K | ﹤0.01% | 3101 |
|
|
2026
Q1 | $205K | Buy |
129,924
+15
| +0% | +$25 | ﹤0.01% | 3299 |
|
|
2025
Q4 | $217K | Sell |
129,909
-88,365
| -40% | -$153K | ﹤0.01% | 3335 |
|
|
2025
Q3 | $369K | Buy |
218,274
+149,999
| +220% | +$178K | ﹤0.01% | 3256 |
|
|
2025
Q2 | $62K | Sell |
68,275
-434,918
| -86% | -$258K | ﹤0.01% | 3439 |
|
|
2025
Q1 | $227K | Buy |
503,193
+86,970
| +21% | +$51K | ﹤0.01% | 3240 |
|
|
2024
Q4 | $209K | Hold |
416,223
| – | – | ﹤0.01% | 3321 |
|
|
2024
Q3 | $377K | Sell |
416,223
-192
| -0% | -$178 | ﹤0.01% | 3237 |
|
|
2024
Q2 | $415K | Buy |
416,415
+50,463
| +14% | +$55.7K | ﹤0.01% | 3268 |
|
|
2024
Q1 | $542K | Buy |
365,952
+2,737
| +0.8% | +$3.1K | ﹤0.01% | 2994 |
|
|
2023
Q4 | $396K | Hold |
363,215
| – | – | ﹤0.01% | 3160 |
|
|
2023
Q3 | $429K | Hold |
363,215
| – | – | ﹤0.01% | 3097 |
|
|
2023
Q2 | $512K | Buy |
363,215
+295,032
| +433% | +$408K | ﹤0.01% | 3043 |
|
|
2023
Q1 | $102K | Buy |
68,183
+22,638
| +50% | +$31.6K | ﹤0.01% | 3246 |
|
|
2022
Q4 | $53.3K | Hold |
45,545
| – | – | ﹤0.01% | 3344 |
|
|
2022
Q3 | $52K | Hold |
45,545
| – | – | ﹤0.01% | 3322 |
|
|
2022
Q2 | $72K | Sell |
45,545
-286,861
| -86% | -$378K | ﹤0.01% | 3332 |
|
|
2022
Q1 | $512K | Buy |
332,406
+17,052
| +5% | +$26.5K | ﹤0.01% | 3097 |
|
|
2021
Q4 | $773K | Hold |
315,354
| – | – | ﹤0.01% | 3010 |
|
|
2021
Q3 | $795K | Sell |
315,354
-7,007
| -2% | -$18K | ﹤0.01% | 2963 |
|
|
2021
Q2 | $919K | Buy |
322,361
+274,194
| +569% | +$709K | ﹤0.01% | 2964 |
|
|
2021
Q1 | $114K | Sell |
48,167
-18,013
| -27% | -$43.3K | ﹤0.01% | 3372 |
|
|
2020
Q4 | $117K | Hold |
66,180
| – | – | ﹤0.01% | 3307 |
|
|
2020
Q3 | $62K | Hold |
66,180
| – | – | ﹤0.01% | 3273 |
|
|
2020
Q2 | $58K | Sell |
66,180
-167,507
| -72% | -$147K | ﹤0.01% | 3256 |
|
|
2020
Q1 | $194K | Hold |
233,687
| – | – | ﹤0.01% | 3016 |
|
|
2019
Q4 | $208K | Hold |
233,687
| – | – | ﹤0.01% | 3034 |
|
|
2019
Q3 | $230K | Hold |
233,687
| – | – | ﹤0.01% | 3022 |
|
|
2019
Q2 | $258K | Hold |
233,687
| – | – | ﹤0.01% | 3052 |
|
|
2019
Q1 | $307K | Sell |
233,687
-2,097
| -0.9% | -$2.61K | ﹤0.01% | 2934 |
|
|
2018
Q4 | $216K | Buy |
235,784
+1,634
| +0.7% | +$2.5K | ﹤0.01% | 3008 |
|
|
2018
Q3 | $482K | Buy |
234,150
+35,433
| +18% | +$74.4K | ﹤0.01% | 2852 |
|
|
2018
Q2 | $359K | Hold |
198,717
| – | – | ﹤0.01% | 2907 |
|
|
2018
Q1 | $468K | Buy |
198,717
+34,354
| +21% | +$80.6K | ﹤0.01% | 2750 |
|
|
2017
Q4 | $310K | Buy |
164,363
+43,891
| +36% | +$95.8K | ﹤0.01% | 2868 |
|
|
2017
Q3 | $300K | Sell |
120,472
-65,951
| -35% | -$164K | ﹤0.01% | 2870 |
|
|
2017
Q2 | $514K | Buy |
186,423
+63,550
| +52% | +$178K | ﹤0.01% | 2684 |
|
|
2017
Q1 | $371K | Hold |
122,873
| – | – | ﹤0.01% | 2750 |
|
|
2016
Q4 | $389K | Hold |
122,873
| – | – | ﹤0.01% | 2748 |
|
|
2016
Q3 | $420K | Buy |
122,873
+27,432
| +29% | +$75.8K | ﹤0.01% | 2674 |
|
|
2016
Q2 | $218K | Hold |
95,441
| – | – | ﹤0.01% | 2906 |
|
|
2016
Q1 | $240K | Sell |
95,441
-8,017
| -8% | -$17.9K | ﹤0.01% | 2839 |
|
|
2015
Q4 | $343K | Hold |
103,458
| – | – | ﹤0.01% | 2810 |
|
|
2015
Q3 | $251K | Hold |
103,458
| – | – | ﹤0.01% | 2893 |
|
|
2015
Q2 | $304K | Hold |
103,458
| – | – | ﹤0.01% | 2877 |
|
|
2015
Q1 | $415K | Hold |
103,458
| – | – | ﹤0.01% | 2696 |
|
|
2014
Q4 | $312K | Hold |
103,458
| – | – | ﹤0.01% | 2831 |
|
|
2014
Q3 | $263K | Hold |
103,458
| – | – | ﹤0.01% | 2859 |
|
|
2014
Q2 | $255K | Buy |
103,458
+40,268
| +64% | +$90.9K | ﹤0.01% | 2928 |
|
|
2014
Q1 | $168K | Hold |
63,190
| – | – | ﹤0.01% | 2985 |
|
|
2013
Q4 | $184K | Hold |
63,190
| – | – | ﹤0.01% | 2970 |
|
|
2013
Q3 | $201K | Sell |
63,190
-23,421
| -27% | -$74.1K | ﹤0.01% | 2916 |
|
|
2013
Q2 | $289K | Buy |
+86,611
| New | +$277K | ﹤0.01% | 2744 |
|
Other funds holding LCTX
BC
DC
RA
Charles Schwab's LCTX Position: Q2 2026 in Review
Charles Schwab increased its Lineage Cell Therapeutics (LCTX) stake by 344% in Q2 2026, buying an estimated $618K and bringing the position to 577,435 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #3101.
Charles Schwab first reported a position in LCTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $919K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- Charles Schwab held 577,435 shares of Lineage Cell Therapeutics worth $756K as of Q2 2026.
- Charles Schwab bought 447,511 Lineage Cell Therapeutics shares in Q2 2026, an estimated $618K.
- Lineage Cell Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3101 holding.
- Charles Schwab first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Lineage Cell Therapeutics position peaked at $919K in Q2 2021.
- 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.